Home / Drugs
Drugs and platforms
Names come from registry InterventionName fields and common brand aliases. We do not rank which drug is better.
Semaglutide
A GLP-1 weekly shot (and a daily pill) being tested far beyond diabetes — obesity, heart, kidney, liver, and addiction studies.
Tirzepatide
A dual GIP/GLP-1 weekly shot. Trials now cover weight, sleep apnea, heart failure, and fatty liver.
Retatrutide
An investigational triple-agonist studied for obesity and metabolic disease.
Pembrolizumab
A PD-1 immunotherapy used across many cancers. New trials test earlier use, combinations, and shorter courses.
Nivolumab
A PD-1 immunotherapy studied alone and with ipilimumab or chemotherapy.
Trastuzumab deruxtecan
An HER2-directed antibody-drug conjugate studied in breast, lung, gastric, and other tumors.
Osimertinib
An EGFR tyrosine-kinase inhibitor studied in lung cancer and related settings.
Sotorasib
A KRAS G12C inhibitor studied in lung cancer and other G12C tumors.
Lecanemab
An anti-amyloid antibody for early Alzheimer's. Trials look at prevention, dosing, and who is most likely to benefit.
Donanemab
Another anti-amyloid Alzheimer's antibody. Studies compare it with similar drugs and test stopping rules.
Ketamine
Rapid-acting depression treatment. Trials test dose, route (IV vs. nasal), and how to keep the effect from fading.
Psilocybin
A psychedelic being studied for depression, addiction, and end-of-life distress — always with therapy, not as a take-home pill.
CAR-T therapy
A patient's own immune cells are reprogrammed to attack cancer. Trials are expanding from blood cancers into solid tumors and autoimmune disease.
Dupilumab
An IL-4/IL-13 antibody studied in asthma, eczema, eosinophilic diseases, and COPD-overlap trials.
Ocrelizumab
A B-cell antibody used in multiple sclerosis. Trials test earlier use, dosing, and progressive disease.
Ofatumumab
A B-cell therapy studied in multiple sclerosis and, in other records, hematologic disease.
Empagliflozin
An SGLT2 inhibitor studied in diabetes, heart failure, and kidney disease.
Dapagliflozin
An SGLT2 inhibitor with heart-failure, CKD, and diabetes studies on the registry.
Adalimumab
A TNF blocker studied across inflammatory diseases, including biosimilar protocols.
Risankizumab
An IL-23 antibody studied in psoriasis, psoriatic arthritis, and IBD.
Tezepelumab
A TSLP antibody studied in severe asthma and related airway disease.
Faricimab
A bispecific eye injection studied in wet AMD and diabetic macular edema.
Lenacapavir
A long-acting HIV capsid inhibitor studied in treatment and prevention records.
Palbociclib
A CDK4/6 inhibitor studied mainly in hormone-receptor-positive breast cancer.